The retinoic acid receptor-related orphan receptor-α (RORα) is an important regulator of various biological processes, including cerebellum development, circadian rhythm and cancer. Here, we show that hepatic RORα controls lipid homeostasis by negatively regulating transcriptional activity of peroxisome proliferators-activated receptor-γ (PPARγ) that mediates hepatic lipid metabolism. Liver-specific Rorα-deficient mice develop hepatic steatosis, obesity and insulin resistance when challenged with a high-fat diet (HFD). Global transcriptome analysis reveals that liver-specific deletion of Rorα leads to the dysregulation of PPARγ signaling and increases hepatic glucose and lipid metabolism. RORα specifically binds and recruits histone deacetylase 3 (HDAC3) to PPARγ target promoters for the transcriptional repression of PPARγ. PPARγ antagonism restores metabolic homeostasis in HFD-fed liverspecific Rorα deficient mice. Our data indicate that RORα has a pivotal role in the regulation of hepatic lipid homeostasis. Therapeutic strategies designed to modulate RORα activity may be beneficial for the treatment of metabolic disorders.
O besity is a high-risk metabolic disorder, leading to various complications, including cardiovascular disease, hyperlipidemia and type II diabetes [1] [2] [3] . Ectopic accumulation of fat in various tissues activates numerous cellular stress and inflammatory signaling pathways, resulting in insulin resistance, pancreatic β-cell dysfunction, and hepatic steatosis 4 . The liver is the central metabolic organ to regulate key aspects of glucose and lipid metabolism including gluconeogenesis, fatty acid β-oxidation, lipoprotein uptake and secretion and lipogenesis 5 . Given that portal vein is a critical path to convey insulin signaling from pancreas during fed state, the hepatic glucose and lipid metabolism are directly under control of nutrient signaling.
Dysregulation of hepatic lipid metabolism results in the development of hepatic steatosis, contributing to the chronic insulin resistance and steatotic hepatitis 6, 7 . The hepatic metabolic pathways are governed by highly dynamic transcriptional networks of orphan nuclear receptors (ONRs), including proliferators-activated receptor-γ (PPARγ), farnesoid X receptor, and liver X receptor 8 . ONRs are ligand-activated transcription factors with no defined ligands 9, 10 . Many ONRs are expressed in tissues involved in metabolism, such as skeletal muscle, adipose tissue and liver 11, 12 , and play critical roles in the regulation of metabolism 13 . Genetic studies have shown that many ONRs regulate nutrient metabolism and physiology of obesity and type II diabetes [14] [15] [16] . Given that numerous synthesized ligands for ONRs are used for developing putative drugs for human metabolic diseases [17] [18] [19] , ONRs are emerging as therapeutic targets for the treatment of metabolic diseases.
Previously, we have reported that receptor-related orphan receptor-α (RORα), a member of ONRs, possesses tumor suppressive function by transrepressing canonical Wnt/β-catenin signaling leading to inhibition of colon cancer growth and by increasing p53 stability upon DNA damage response 20, 21 . RORα is known to regulate cerebellum development 22 . The staggerer (sg) mice, natural Rorα spontaneous mutant mice, display ataxia and severe cerebellar atrophy 23 . Moreover, RORα functions to regulate circadian rhythm as a key regulator of the cyclic expression of BMAL1 together with REV-ERBα 24 . The RORα/REV-ERBα feedback loop controls the circadian expression pattern of BMAL1, indicating that RORα plays a key role in the core circadian clock 25 . In addition, sg mice show lower expression levels of genes involved in lipid metabolism, including apolipoprotein A-1 (apoA1) and apolipoprotein C-III (apoCIII) 26, 27 . Thus, sg mice exhibit less body weight gain compared with wild-type (WT) mice 28 . Given that sg mice have huge cerebellar defects, it is still possible that physiological changes observed in sg mice are indirect effects. Thus, the physiological roles of RORα to control transcriptional networks to modulate lipogenesis and gluconeogenesis still remain unclear.
Here, we report that RORα plays a key role to control hepatic lipid metabolism to protect against diet-induced obesity and hepatic steatosis, using liver-specific Rorα-deficient mouse model. High-fat diet (HFD)-fed liver-specific Rorα deficient mice (RORα LKO mice) show severe metabolic defects, including hepatic steatosis, obesity, and insulin resistance, although no physiological changes have been observed with control diet (CD). Genome-wide transcriptome analysis reveals that PPARγ signaling is remarkably elevated in RORα LKO mice. RORα specifically recruits HDAC3 to the PPARγ target promoters to suppress PPARγ transcriptional activity. Finally, PPARγ antagonism by using PPARγ antagonist GW9662, largely ameliorates body weight gain and hepatic steatosis in HFD-fed RORα LKO mice, indicating that dysregulated PPARγ signaling is a critical metabolic cue, leading to metabolic defects in HFD-fed RORα LKO mice. Together, our data demonstrate that RORα controls PPARγ signaling to protect against hepatic metabolic homeostasis and obesity in response to HFD.
Results
HFD induces obesity in liver-specific Rorα-deficient mice.
To determine the physiological roles of RORα in the liver, we generated RORα-floxed mice (RORα f/f ) by gene targeting in ES cells and crossed RORα floxed mice with Albumin-Cre (Alb-Cre) mice to selectively create liver-specific Rorα conditional knockout (KO) mice (hereafter named RORα LKO ) ( Fig. 1a, b) . The mRNA and protein levels of endogenous hepatic RORα were remarkably depleted in RORα LKO mice compared with littermate controls (hereafter named RORα f/f ) ( Fig. 1c-f ). We measured the growth rate of RORα LKO mice and observed that they attained body weights similar to RORα f/f mice fed CD during 10 weeks from 8 weeks old (Fig. 1g ). Body composition analysis revealed that RORα LKO mice exhibited similar fat/lean mass, free body fluid and adipocytes size with those of RORα f/f ( Supplementary Fig. 1a , b). However, when placed on a HFD, RORα LKO mice exhibited a significant increase of the weight gain (20 vs. 25 g) compared with their RORα f/f littermates, resulting in extraordinary obesity ( Fig. 1g ). Body composition analysis and macroscopic view revealed that RORα LKO mice had more fat mass ( Fig. 1h , i). All white and brown fat depots from RORα LKO mice were significantly increased in mass relative to RORα f/f ( Fig. 1j ). During obesity, adipose tissue expands by hyperplastic and/or hypertrophic growth. The cross-sectional area of adipocytes in visceral fat tissue was markedly increased in RORα LKO mice compared with RORα f/f mice (Fig. 1k ). Induction of pro-inflammatory genes, including Mcp1, Ifnγ, and F4/80 in visceral fat depot were potentiated in RORα LKO mice ( Fig. 1l ). Consistent with a significant weight gain in HFD-fed RORα LKO mice, gene expression analysis revealed reduction of Pgc1α, as well as a number of genes involved in thermogenesis, mitochondrial biogenesis, and fatty acid oxidation in brown adipose tissue of RORα LKO mice compared with that of RORα f/f littermates (Fig. 1m ). The observation that energy expenditure (EE) in brown fat has been impaired in HFD-fed RORα LKO mice led us to examine whether they have global metabolic defects. Although no obvious defects were observed in mice on CD ( Supplementary Fig. 1c ), HFD-fed RORα LKO mice were found to produce far less CO 2 , consume less O 2 and expend less energy than RORα f/f littermates, indicating that oxidative phosphorylation is impaired by the hepatic deletion of RORα ( Fig. 1n and Supplementary Fig. 1d ). Previously, bile acids have been reported to increase EE by promoting intracellular thyroid hormone activation in brown adipose tissue 29 . We observed that expression of key genes involved in hepatic bile acid synthesis was remarkably reduced in HFD-fed RORα LKO mice ( Supplementary  Fig. 1e ). Consistently, serum bile acid pool sizes in HFD-fed RORα LKO mice were markedly less than RORα f/f littermates ( Supplementary Fig. 1f ), implicating that reduction of bile acid synthesis and bile acid pool size led to reduced EE in brown adipose tissue of HFD-fed RORα LKO mice.
Hepatic steatosis impairs insulin sensitivity in RORα LKO mice.
Obesity is largely associated with hepatic steatosis in humans as well as in rodents. Consistent with obese phenotype in RORα LKO mice, large lipid vesicles with increased amounts were observed in the hepatocytes of HFD-fed RORα LKO mice ( Fig. 2a ). Macroscopically, liver from HFD-fed RORα LKO mice was markedly enlarged and paler compared with HFD-fed RORα f/f liver (Fig. 2b) . Consistently, HFD-fed RORα LKO mice exhibited a remarkable increase of liver weight compared with HFD-fed RORα f/f mice (Fig. 2c ). In accordance with hematoxylin and eosin staining, oil red O staining and hepatic triglyceride (TG) analysis showed a dramatic increase in lipid level in the HFD-fed RORα LKO liver compared with the HFD-fed RORα f/f liver, whereas no difference was observed in CD-fed RORα f/f and RORα LKO mice (Fig. 2d , e and Supplementary Fig. 1g ). While hepatic gene expression profiles were similar among CD-fed genotypes ( Supplementary Fig. 1h ), hepatic gene expression profiles of lipogenesis, gluconeogenesis, and lipid sequestration in the HFD-fed RORα LKO were largely increased, indicating that RORα protects against HFD-induced hepatic steatosis ( Fig. 2f ). Rel. mRNA level Obesity and hepatic steatosis often predispose rodents and humans to impaired glucose homeostasis and insulin resistance [30] [31] [32] . Hepatic deficiency of RORα resulted in elevated fasting insulin levels in RORα LKO mice ( Fig. 2g ). As elevated fasting insulin level is an indication of insulin resistance, RORα LKO mice predisposed to severe insulin resistance than RORα f/f mice. Consistent with elevated fasting insulin level, an investigation of insulin signaling pathways confirmed reduction of phosphorylated AKT, indicating that insulin signaling was impaired in HFD-fed RORα LKO mice ( Fig. 2h ). As insulin signaling was impaired in the liver, we performed glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) to determine if glucose homeostasis was impaired in HFD-fed RORα LKO mice. Glucose intolerance and insulin resistance were observed in HFD-fed RORα LKO mice, although CD-fed RORα LKO mice exhibited little or no difference in glucose homeostasis compared with CD-fed RORα f/f mice (Fig. 2i, j) . Altogether, our data strongly demonstrate that hepatic RORα is required for prevention against insulin resistance.
RORα LKO mice exhibit enhanced PPARγ transcriptional activity. To explore molecular mechanism by which hepatic deletion of RORα induces obesity and insulin resistance, we performed mRNA-sequencing analysis of liver tissues obtained from HFD-fed RORα f/f , HFD-fed RORα LKO , CD-fed RORα f/f and CD-fed RORα LKO mice (Supplementary Data Table 1 ). Using the resulting mRNA expression profiles, we first identified 343 differentially expressed genes (DEGs; see Methods) between HFD-fed RORα LKO . We categorized these DEGs into eight groups (Groups 1-8) based on differential expression patterns in the three comparisons above. Our data above showed that we only found significant weight gain of RORα LKO mice under HFD condition. Of Groups 1-8, thus, we first focused on Groups 1-4 showing significant changes under HFD condition ( Fig. 3a ).
To understand cellular processes represented by Groups 1-4, we performed enrichment analysis of gene ontology biological processes (GOBPs) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for the genes in Groups 1-4 using DAVID software 33, 34 (Supplementary Data 3). Group 1 is mainly involved in the processes related to PPAR and adipocytokine signaling pathways and fatty acid/retinol metabolism ( Fig. 3b ). Group 4 is mainly involved in the processes related to circadian rhythm (Supplementary Data 3). Since Group 1 is highly associated with the weight gain of HFD-fed RORα LKO , we next examined which transcription factors (TFs) account for up-regulation of the genes in Group 1 under HFD condition. By performing TF enrichment analysis of the genes in Group 1 using ChEA2 software 35 , PPARγ turned out to be the most enriched TF in Group 1 ( Fig. 3c and Supplementary Data 4). Quantitative PCR with reverese transcription analysis confirmed that the genes in Group 1 including PPARγ target genes are largely elevated in HFD-fed RORα LKO mice ( Fig. 3d ), indicating that PPARγ transcriptional activity is enhanced in the absence of RORα.
PPARα is a transcriptional factor that conducts a key role in hepatic lipid metabolism and shares similar response elements with PPARγ on the target promoters 36, 37 . To determine whether RORα also mediates PPARα transcriptional network in the liver, we examined the expression of well-known hepatic PPARα target genes, including Acox1 and Fgf21. The hepatic gene expressions of Acox1 and Fgf21 in HFD-fed RORα LKO mice were similar to those of HFD-fed RORα f/f mice, suggesting that RORα deficiency would not further enhance hepatic PPARα transcriptional network ( Supplementary Fig. 2a ) under HFD condition. We next examined the expression of PPARα target genes in the physiological setting of PPARα activation. It has been widely accepted that PPARα is activated under conditions of energy deprivation 38 . The induction of PPARα target genes in RORα LKO mice was quite similar to that of RORα f/f mice ( Supplementary  Fig. 2b ). Chromatin immunoprecipitation (ChIP) assay clearly revealed little or no difference of PPARα recruitment to PPARresponse element (PPRE) on the promoters of PPARα target genes ( Supplementary Fig. 2c ). Recently, PPARα has been reported to bind autophagic gene promoters to coordinate autophagy in response to nutrient deprivation 37 . We observed that the induction of autophagic genes including LC3a and Sesn2 of RORα LKO mice were similar to those of RORα f/f mice ( Supplementary Fig. 2d ). Taken together, these data indicate that RORα mainly controls PPARγ transcriptional network rather than PPARα in the liver in response to environmental stress such as HFD.
RORα represses PPARγ transcriptional activity via HDAC3.
Since PGC1α is a well-known coactivator for PPARγ 39 , we examined whether introduction of RORα inhibits PPARγ/ PGC1α-dependent transcriptional activation using PPREcontaining luciferase reporter. Expression of PGC1α Expression was normalized to L32 expression. n Metabolic cage studies were performed in RORα f/f and RORα LKO mice (n = 5-6 mice/group). O 2 consumption (VO 2 ), CO 2 production (VCO 2 ) and energy expenditure were represented (left to right). Statistical analysis was performed using Student's unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001, NS, Non-Significant. Data expressed as mean ± s.e.m dramatically increased PPARγ transcriptional activity, and increased expression of RORα progressively attenuated the PPARγ/PGC1α-dependent transcriptional activation (Fig. 4a ). In addition, we examined whether RORα inhibits NCOA1 and NCOA2-mediated PPARγ transcriptional activation. NCOA1 and NCOA2, as p160 family members, are also coactivators for PPARγ 40 . Consistently, RORα significantly reduced NCOA1 and NCOA2-mediated transcriptional activation ( Fig. 4b and Supplementary Fig. 3a ).
To evaluate the role of RORα in attenuation of the PPARγ-dependent transcriptional activation, we treated Hep3B cells with rosiglitazone, a PPARγ synthetic agonist, and then measured PPRE-luciferase activity. Knockdown of RORα markedly enhanced PPRE-luciferase activity, indicating that RORα functions to repress PPARγ transcriptional activity ( Fig. 4c ). To determine if DNA-binding domain (DBD) of RORα is required for inhibiting PPARγ transcriptional activation, we introduced DBD-deleted RORα mutant (RORα ΔDBD). We observed 
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As RORα failed to interact with PPARγ, our data proposed that RORα suppresses PPARγ transcriptional activation through DBD and possibly competes with PPARγ for the binding to PPRE. Consistently, the recruitment of RORα was markedly reduced in PPRE-deleted synthetic promoter region ( Supplementary Fig. 3b , c).
Since histone acetylation promotes transcriptional activation, we next examined whether RORα interacts with specific histone deacetylases for the repression of PPARγ transcriptional activity. Co-immunoprecipitation assay revealed that RORα specifically interacts with HDAC3 ( Fig. 4e and Supplementary Fig. 3d ). To determine if HDAC3 is required for RORα-mediated repression of PPARγ transcriptional activity, we further examined repressive function of HDAC3 for PPRE-luciferase activity in the presence or absence of RORα. Intriguingly, knockdown of RORα relieved the HDAC3-dependent repressive function indicating that HDAC3 exerted repressive function on PPARγ transcriptional activity in the presence of RORα (Fig. 4f ). Consistently, knockdown of HDAC3 largely reversed RORα-mediated repression of PPARγ transcriptional activity (Fig. 4g, h and Supplementary Fig. 3e ). These results indicate that RORα recruits HDAC3 to potentiate repression of PPARγ transcriptional activity.
RORα/HDAC3 dynamically regulate PPARγ target gene expression. PPRE consists of a direct repeat (DR) sequence of (A/G)GGTCA spaced by one nucleotide, whereas consensus RORα response element (RORE) consists of core motif (A/G) GGTCA preceded by a 6-bp A/T-rich sequence. Thus, given that RORE and PPRE share core motif, we hypothesized that RORα directly binds the PPRE of PPARγ target promoters for transcriptional repression. To examine whether RORα and . Hierarchical clustering of the DEGs in Groups 1-8 (Euclidian distance as a dissimilarity measure and average linkage) were used to display the log 2 -fold changes. b KEGG pathways enrichment analysis for the genes in Group 1. The bars represent the enrichment scores, -log 10 (P value). c TF enrichment analysis for the genes in Group 1 using ChEA2 software. Top 3 TFs are shown. The bars represent the enrichment scores, -log 10 (P value). d Expression levels of group 1 genes (upregulated genes in RORα LKO mice fed HFD compared with RORα f/f mice) in liver extract from RORα f/f and RORα LKO mice fed CD or HFD for 10 weeks (n = 5-9/ group) as determined by qRT-PCR. Expression was normalized to 36B4 expression. Statistical analysis was performed using two-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001. Data expressed as mean ± s.e.m HDAC3 are co-recruited to the PPARγ target promoters for the repression, we performed ChIP assay with anti-RORα, PPARγ, PPARα, RNA polymerase II (Pol II), acetylated H3 (H3Ac) and HDAC3 antibodies from the mouse liver extracts of CD or HFD-fed RORα f/f and RORα LKO mice. ChIP assays revealed that RORα and HDAC3 were co-recruited to the Cd36, Scd1 and Plin2 promoters in the liver of HFD-fed RORα f/f mice, although no changes were observed with CD-fed RORα f/f mice ( Fig. 5a and Supplementary Fig. 4a, b ). In the absence of RORα, PPARγ recruitment was markedly increased, whereas HDAC3 recruitment was largely diminished along with elevated acetylated H3 levels on the Cd36, Scd1 and Plin2 promoters in the liver of HFDfed RORα LKO mice ( Fig. 5a and Supplementary Fig. 4a, b ). Unlike PPARγ, PPARα recruitment was barely detected from the PPARγ target promoters containing PPRE as assessed by ChIP assay ( Fig. 5a and Supplementary Fig. 4b, c) .
We next determined if both RORα and HDAC3 are recruited to the PPRE in response to PPARγ agonist in Hep3B cells ( Supplementary Fig. 5a ). Treatment of rosiglitazone largely induced the expression of PPARγ target genes ( Supplementary  Fig. 5b ). Interestingly, 8 h washout after rosiglitazone treatment dramatically reduced PPARγ target gene expressions ( Supplementary Fig. 5a, b) . Consistent with gene expressions, treatment of rosiglitazone increased recruitment of PPARγ, PGC1α and Pol II with elevated histone H3 acetylation level on PPARγ target promoters as well as induction of PPARγ target Fig. 5b and Supplementary Fig. 5c ). Strikingly, further increased recruitment of RORα to PPRE was observed along with enhanced HDAC3 recruitment in the setting of washout of rosiglitazone for 8 h ( Fig. 5b and Supplementary Fig. 5c ). Increased recruitment of RORα and HDAC3 substantially diminished PGC1α and Pol II recruitment on PPRE with decreased histone H3 acetylation level on PPRE ( Fig. 5b and Supplementary Fig. 5c ).
Next, we further determined whether PPARγ antagonist GW9662 also resulted in the increased recruitment of RORα and HDAC3 to the PPARγ target promoters. Consistent with the results from 8 h washout, GW9662 treatment significantly reduced the expression levels of PPARγ target genes (Supplementary Fig. 6a ). ChIP assay revealed that recruitment of RORα and HDAC3 to the PPARγ target promoters were markedly increased, while PPARγ and Pol II recruitments were markedly reduced in response to GW9662 treatment ( Supplementary  Fig. 6b ).
RORα competes with PPARγ for binding to PPARγ target promoters. To address HDAC3 recruitment to PPARγ target gene promoters requires RORα, we first examined the PPARγ target gene induction in the presence or absence of RORα. The induction of PPARγ target genes by rosiglitazone was further enhanced by RORα siRNA, indicating that RORα is a critical transcriptional repressor for PPARγ target gene expression ( Supplementary Fig. 7a ). RORα knockdown largely increased the recruitment of PPARγ for transcriptional activation with increased levels of H3 acetylation to the PPARγ target gene promoters ( Fig. 6a and Supplementary Fig. 7b ). While remarkably increased by rosiglitazone washout, the HDAC3 recruitment was substantially reduced by RORα knockdown even with setting of rosiglitazone washout ( Fig. 6a and Supplementary Fig. 7b ). Taken together, these data clearly indicate that RORα is required for recruitment of HDAC3 to PPARγ target gene promoters.
To determine if RORα competes with PPARγ for the binding to the PPARγ target promoters, we transiently knocked down PPARγ in Hep3B cells. To mimic HFD feeding conditions in vitro, we treated cells with free fatty acid (FFA) and examined expression of PPARγ target genes. We observed that FFA treatment markedly increased PPARγ target gene expressions in both WT and Pparα-null mouse primary hepatocytes, indicating that PPARα failed to influence on PPARγ transcriptional network in the setting of HFD ( Supplementary Fig. 7c ). Next, we tested PPARγ target gene expressions in the presence of PPARγ siRNA or HDAC3 siRNA. While repressed by PPARγ siRNA, expression of PPARγ target genes was largely enhanced by HDAC3 siRNA in response to FFA treatment ( Supplementary Fig. 7d ). Consistent with gene expression, increased PPARγ recruitment by FFA was substantially diminished by PPARγ siRNA (Fig. 6b ). Interestingly, recruitment of RORα was dramatically increased to the PPARγ target gene promoters, and HDAC3 recruitment was accompanied by the RORα recruitment to PPARγ target promoters by knockdown of PPARγ (Fig. 6b ). Furthermore, Re-ChIP assay clearly indicated that PPARγ and RORα are able to bind to the same genomic region and their recruitments to promoter of target genes are mutually exclusive ( Supplementary Fig. 7e ). These data strongly indicate that RORα and HDAC3 compete with PPARγ for the binding to the target gene promoters for regulation of gene expressions with opposite transcriptional outputs. Altogether, our data demonstrate that RORα functions as a corepressor along with HDAC3 and is co-recruited to the PPARγ target promoters for the repression of PPARγ-mediated transcriptional activity.
To determine whether RORα recruitment is accompanied by the presence of HDAC3, we examined recruitment of RORα to the PPARγ target gene promoters in the presence of HDAC3 siRNA. Although little or no difference of the recruitment of RORα and PPARγ was observed, Pol II recruitment to the PPARγ target gene promoters was markedly increased by HDAC3 knockdown (Fig. 6c) , indicating that the presence of HDAC3 affected the recruitment of RNA polymerase II to the PPARγ target gene promoters. Taken together, these data indicate that both RORα and HDAC3 serve as transcriptional corepressors on the PPARγ target gene promoters for the repression of PPARγ target gene expressions.
PPARγ antagonism restores metabolic homeostasis in RORα LKO mice. Since RORα turned out to play a key role to repress PPARγ transcriptional activity in vitro and in vivo, we next examined if inhibition of PPARγ transcriptional activities restores impaired metabolic homeostasis. For this, PPARγ antagonist GW9662 were treated to RORα f/f and RORα LKO mice for 5 weeks with HFD. Intriguingly, the body weight gain of both RORα f/f and RORα LKO mice were markedly reduced by GW9662 treatment compared with vehicle-treated control mice (Fig. 7a ). The reduction of body weight gain by GW9662 in RORα LKO mice was much greater, leading to similar body weight to GW9662-treated RORα f/f mice, indicating that inhibition of PPARγ activity remarkably reduces body weight gain in RORα LKO mice (Fig. 7a ). Similar to reduced body weight gain, tissue weights of the liver and epidydimal white adipose tissue were markedly reduced by GW9662 treatment in both RORα f/f and RORα LKO mice (Fig. 7b, c) . Consistently, crosssectional area of adipocytes was significantly reduced by GW9662 treatment (Fig. 7d ). In accordance with body weight reduction, PPARγ antagonism markedly reduced hepatic steatosis in both RORα f/f and RORα LKO mice (Fig. 7e) . Consistently, gene expression profile analysis exhibited that target gene expression levels involved in hepatic gluconeogenesis and lipogenesis are largely reduced by GW9662 treatment (Fig. 7f, g) . Together, we demonstrate that enhanced PPARγ transcriptional activity by RORα deficiency is de-activated by PPARγ antagonism to restore metabolic homeostasis, including body weight gain, hepatic steatosis and glucose and lipid metabolism.
Discussion
Hepatic nuclear receptors play critical roles in the regulation of lipid and glucose metabolism in response to environmental stress, including nutrient and hormonal cues 41 . Dysfunction of hepatic nuclear receptors is largely linked to metabolic diseases including obesity and type II diabetes. We found that PPARγ signaling is a critical pathway affected by hepatic deletion of RORα. Dysregulated PPARγ signaling in RORα LKO mice results in uncontrolled lipogenesis, contributing to the development of hepatic steatosis and diet-induced obesity on a HFD. Furthermore, treatment of PPARγ antagonist GW9662 decreased the susceptibility to obesity 42, 43 . Consistent with previous reports, we also observed that elevated PPARγ transcriptional activity in RORα LKO mice are downregulated after treatment of GW9662, resulting in decrease of diet-induced hepatic steatosis and obesity. Our data confirm that RORα is a key factor for the repression of PPARγ signaling to protect against diet-induced hepatic steatosis and obesity in vivo.
Together, PPARγ signaling turns out to be significantly activated in HFD-fed RORα LKO mice while increased RORα reduces PPARγ transcriptional activity, providing a direct molecular link between RORα and PPARγ. Furthermore, our data indicate that RORα regulates PPARγ signaling through RORα-mediated HDAC3 recruitment to the PPARγ target promoters. Thus, RORα plays a crucial role in maintaining homeostasis of lipid metabolism in liver by negatively regulating PPARγ signaling via HDAC3 recruitment to the PPARγ target promoters for transcriptional repression (Fig. 7h) .
Thiazolidinedione (TZD) is a synthetic PPARγ agonist and has been clinically approved to improve glucose homeostasis and fatty liver in human patients. Although the molecular mechanisms still remain unclear, the 'lipid steal' hypothesis has been widely accepted to explain of how TZD treatment improves insulin resistance in type II diabetes patients [44] [45] [46] . However, though PPARγ activation has shown to reduce blood glucose level and hepatic gluconeogenesis, and improve glucose tolerance 47, 48 , several reports have shown that PPARγ activation leads to hepatic steatosis 49, 50 . In general, the expression of PPARγ is very low in human and mouse liver. Interestingly, the expression level of hepatic PPARγ is significantly upregulated in obese rodent model 51 and high level of PPARγ in mouse liver is sufficient for the induction of adipogenic transformation of hepatocytes with adipose tissue-specific gene expression and lipid accumulation 52 . These data indicate that PPARγ plays a key role in development of hepatic steatosis. Accordingly, inhibition of PPARγ signaling and hepatic deficiency of PPARγ in ob/ob mice have shown to ameliorate fatty liver 53, 54 . A recent study clearly showed that PPARγ antagonism improves insulin sensitivity, promotes the browning of white adipose tissue and reduces lipogenic and glucogenic gene expressions in the liver to prevent against diet-induced obesity 55 . Intriguingly, liver-specific PPARγ- ARTICLE deficient mice exhibit resistance to HFD-induced hepatic steatosis 56 . Expression of numerous genes involved in lipid uptake and lipid transport was remarkably decreased in the liver-specific PPARγ-deficient mice, resulting in reduction of hepatic steatosis 56 . Altogether, these studies suggest that local activation of hepatic PPARγ may promote ectopic fat deposition in the liver whereas systemic activation of PPARγ may promote fat deposition in adipose tissue rather than liver leading to clinical improvements of metabolic syndromes including hepatic steatosis. Thus, negative control of RORα to suppress hepatic PPARγ activation is important to maintain physiological hepatic lipid homeostasis. Therefore, these results strongly indicate that the PPARγ signaling pathway is involved in diet-induced hepatic steatosis, and hepatic lipid accumulation is prevented by suppression of PPARγ transcriptional network in the liver. It has been widely accepted that PPARα is a major nutrient-sensing PPAR isoform to modulate hepatic gene expressions 37 . As no substantial activation of PPARα has been Acc ## *** observed in the fasted or HFD-fed RORα LKO mice, we believe that RORα mainly controls PPARγ transcriptional network to maintain hepatic homeostasis in response to HFD. However, it has been well established that PPARα is a promising therapeutic target to upregulate beta oxidation gene expressions and inhibit hepatic de novo lipogenesis. Consistently, animal model using PPARα-null mice have been reported to develop remarkable hepatic steatosis 38, 57 . Thus, it is highly possible that hepatic steatosis phenotype in HFD-fed RORα LKO mice may be resulted from both upregulated PPARγ activation and suppressed PPARα transcriptional activity in the absence of RORα. Understanding of the contribution of PPARα transcriptional network with RORα would be critical to delineate the molecular mechanisms of how PPAR isoforms including PPARα and PPARγ modulate hepatic lipid homeostasis with various transcriptional factors in response to environmental stress such as HFD.
It has been reported that RORα may compete with PPARγ for the binding to PPRE 58 . It is well established that PPRE contains a DR1 motif consisting of two core DRs of AGGTCA separated by a single nucleotide 59 . Among nucleotides of DR1 motif, the four nucleotides immediately 5′ of DR1 motif are highly conserved and exhibit a consensus of A(A/T)CT. Previous study has reported that the binding of the DBD of PPARs to the single core binding site requires the AT-rich 5′-extended binding site which is quite similar to the binding site for the monomer of RORα 60 . Thus, the similarity in the binding sequences for PPARγ and RORα appears to allow RORα to modulate PPAR signaling by competing with PPARγ for binding to PPREs 61 .
The physiological role of HDAC3 has been reported to repress hepatic steatosis. In liver-specific Hdac3-deficient mice, little or no body weight change was observed. As HDAC3 regulates the expression of lipogenic genes in an enzymatic activity-independent manner 62 , fasting phase markedly promotes hepatic steatosis in liver-specific Hdac3-deficient mice 63 . An intriguing observation in this study is that RORα is crucial to recruit HDAC3 to repress hepatic PPARγ-mediated lipogenic genes and protect against diet-induced hepatic steatosis and obesity. Furthermore, repressive role of RORα-mediated HDAC3 on lipid metabolism is coupled with elevated hepatic gluconeogenesis. Though hepatic HDAC3 has been shown to promote gluconeogenesis by repressing lipid synthesis and sequestration 63 , we observed notable increase of gene expression involved in hepatic gluconeogenesis in HFD-fed RORα LKO mice. Intriguingly, HDAC3 ablation upregulated hepatic expression of perilipin gene which contributes to lipid sequestration to ameliorate glucose tolerance 63 . We also noticed that perilipin 2, hepatic isoform of perilipin was substantially elevated in HFD-fed RORα LKO mice. Unlike hepatic HDAC3 ablation, impaired RORα-mediated HDAC3 transcriptional repression led to interfere hepatic homeostasis of PPARγ signaling. Therefore, disturbed regulatory mechanism of PPARγ signaling in HFD-fed RORα LKO mice would be the main cause of the insulin resistance and glucose intolerance. Consistent with elevated fasting glucose level in HFD-fed RORα LKO mice, mRNA level of the rate-limiting enzyme, phosphoenol pyruvate carboxykinase (PEPCK), in the hepatic gluconeogenesis pathway, was largely elevated in HFD-fed RORα LKO mice. Together, our data strongly indicate that physiological role of HDAC3 in the liver is to suppress PPARγ transcriptional activity via RORα to control hepatic lipid and glucose metabolism.
Previously, it has been reported that bile acid signaling pathway is critical to modulate EE in brown adipose tissue. Bile acids activates mitogen-activated protein kinase pathways and serve as ligands for the G protein-coupled receptor TGR5 29 . Thus, hepatic bile acid synthesis and bile acid pool size in the serum is critical to control metabolic rate. Bile acids induces cyclic-AMP-dependent thyroid hormone activating enzyme type 2 iodothyronine deiodinase (D2) 29 . Thus, bile acid-TGR5-cAMP-D2 signaling pathway in the brown adipose tissue has been known as a crucial mechanism to modulate EE 29 . We observed that several key genes involved in bile acid synthesis were largely downregulated as well as serum bile acid pool size in HFD-fed RORα LKO mice. Though we still do not know the direct mechanism of how hepatic bile acid signaling was impaired in RORα LKO mice, we speculate that impaired hepatic bile acid synthesis would impair TGR5 activation in brown adipose tissue to reduce EE.
Several of the observed metabolic alterations in the RORα LKO mice are indeed different from those observed in sg mice. For example, RORα LKO mice gain significantly more weight than WT mice and develop hepatic steatosis when fed with HFD. However, sg mice are protected from HFD-induced obesity and fatty liver and display improved insulin sensitivity 28, 64 . A strong difference between these two mouse models is their overall growth condition. RORα LKO mice have no obvious phenotypic abnormalities under normal dietary conditions, whereas sg mice suffer from severe growth retardation that would likely be attributed to a number of developmental defects. In addition, defective RORα function in other tissues including brain is likely to systemically affect energy intake and expenditure in the sg mice, making it difficult to specifically dissect hepatic function of RORα. Therefore, it would be helpful to utilize these two mice and compare their phenotypes in certain conditions together for understanding of RORα function in vivo. Collectively, our data indicate that liver-specific RORα deficient mice were successfully developed and the utilization of the mice allowed us to be able to study in vivo functions of RORα in liver more precisely by excluding the potential secondary effect of sg mice.
In conclusion, our data indicate that RORα requires HDAC3 to regulate PPARγ signaling to maintain lipid homeostasis in response to over-nutrient cue. We demonstrate that major target of RORα in the liver is the PPARγ signaling and lipid/glucose metabolism. Our findings provide a direct link between RORα and hepatic fatty acid and glucose metabolism. Thus, therapeutic strategies designed to modulate RORα activity may be beneficial for the treatment of hepatic disease as well as obesity-associated metabolic diseases.
Methods
Generation of conditional Rorα-deficient mice and animal care. To generate mice with a floxed RORα allele, a 16.5 kb region used to construct the targeting vector was first subcloned from a BAC clone (bMQ-293I20, Source BioScience) into a pBluescript phagemid system. The FRT-flanked puromycin cassette containing a loxP sequence was inserted at the front of exon 4 and the single loxP site was inserted at the back of exon 5. The target region was~15.2 kb which included exons 4 and 5. Twenty micrograms of the targeting vector was linearized by SalI and then electroporated to E14Tg2A ES cells. Surviving clones after puromycin selection were expanded and analyzed by Southern blot to confirm recombinant ES clones. After BamHI digestion, the bands representing WT and mutant alleles are 9.0 and 6.8 kb, respectively. Targeted ES cells were selected for microinjection into C57BL/6 blastocysts to generate chimeras. The male chimeras were bred with C57BL/6 female mice to select for germline transmission. To remove the puromycin selection cassette, targeted heterozygous F1 was crossed with Flp deleter strain (FLPeR mice, The Jackson Laboratory strain 003946). The mice were backcrossed to C57BL/6 then crossed with Alb-Cre mice (The Jackson Laboratory strain 003574) to generate liver-specific Rorα-deficient mice. Male RORα f/f and RORα LKO mice at 8 weeks of age were fed a CD or a 60% kcal fat HFD (Research diet, D12492) during 10 weeks. The sample sizes for all animal studies were announced in each figure legend. Mice were housed in a specific pathogen-free AAALAC-accredited facility under controlled conditions of temperature (25°C) and light (12 h light:12 h dark, lights switched on at 7:00 a.m.). Food and water were available ad libitum. All mice used in these experiments were backcrossed to C57BL/6 at least seven generations. Animals for each group of experiments were chosen randomly. The primers used in PCR analysis for genotyping floxed alleles are: forward 5′-GCTTGTGGGTTTCTCCTACA-3′ and reverse 5′-GCAGCAAGTGTTGTGTCCCA-3′. This study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of National Cancer Center Research Institute.
Body composition. Fat and lean body masses were assessed by 1 H magnetic resonance spectroscopy (Bruker BioSpin).
Indirect calorimetry. Oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), respiratory exchange ratios, EE and food consumption were measured using an indirect calorimetry system PHENOMASTER (TSE System). Mice in each chamber were maintained at a constant environmental temperature of 22°C.
Isolation and culture of primary mouse hepatocytes. Mouse primary hepatocytes were isolated from the liver of 8-week-old male RORα f/f and RORα LKO mice or WT and PPARα null mice by the collagenase perfusion method 65 . Dissociation into individual hepatocytes was performed in Dulbecco's modified Eagles' medium (DMEM) (Welgene) containing 10% heat-inactivated fetal bovine serum (FBS), 1% antibiotics, 20 mM HEPES, 100 nM insulin, 1 nM dexamethasone. For each hepatocyte preparation, cell viability was estimated by the exclusion of trypan blue.
Total bile acid (TBA) measurement. The quantitative determination of total bile acid of mice serum that was collected after centrifugation of mice blood was measured using the total bile acids assay kit (DZ042A-K, Diazyme Laboratories), according to the manufacturer's instructions.
Histology. When mice were euthanized by CO 2 asphyxiation, livers and white adipose tissues (WATs) were rapidly fixed in 10% formalin (Sigma) at 4°C overnight. After fixation, tissues were sequentially dehydrated in ethanol with increasing concentrations ranging from 50 to 100%. Dehydrated specimens were subsequently infiltrated with 100% xylene and embedded in paraffin wax. For hematoxylin and eosin (H&E) staining, tissues were sectioned at 5 μm thickness, deparaffinized, rehydrated and stained with hematoxylin for 3 min followed by counterstaining with eosin for 1 min. For Oil red O staining, fresh samples of liver embedded in OCT tissue freezing medium (Sakura Finetek). 0.5% Oil red O solution was prepared by dissolving 0.5 g Oil red O powder (Sigma) in 100 ml propylene glycol (sigma). Fresh frozen specimens were cryosectioned at 8 μm thickness and air dried. Then fix in ice cold 10% formalin for 10 min, air dried again, and rinsed with distilled water. Sections were placed in 100% propylene glycol for 5 min and stained with pre-warmed 0.5% Oil red O solution in propylene glycol for 15 min in 60°C oven. Then sections were rinsed with distilled water and followed by counterstaining with hematoxylin. Images were acquired using digital microscopes (Leica DMD108, Leica microsystems) equipped with ×10 and ×20 objective lenses.
Quantitative real-time RT-PCR. Total RNAs were extracted using Trizol (Invitrogen) and reverse transcription was performed from 2.5 μg of total RNAs using the M-MLV cDNA Synthesis kit (Enzynomics). The abundance of mRNA was detected by a CFX384 Touch TM Real-Time PCR Detection System (Bio-Rad) with SYBR Green (Enzynomics). The quantity of mRNA was calculated using ΔΔCt method and normalized by using primers indicated in each figure legend. All reactions were performed as triplicates. Primers used for analysis are listed in Supplementary Data 5.
Intraperitoneal glucose or insulin tolerance tests. For GTTs, 2 g of glucose per kg of mice body weight was injected i.p. to overnight fasted mice. For ITTs, 0.75 U of insulin (Humulin R, Eli Lilly) per kg of mice body weight was injected i.p. to 6 h fasted mice. Mice blood was drawn at indicated time intervals from the tail tip puncture, and blood glucose level was measured by accu-check perfoma glucometer (Roche).
Generation of mRNA-sequencing data. Four groups of mice, CD-fed RORα f/f , CD-fed RORα LKO , HFD-fed RORα f/f and HFD-fed RORα LKO mice, were analyzed by RNA-sequencing. Four mice per group were killed, and livers from two mice were pooled to generate two samples per group, that is, duplicate experiments for each group were performed. Total RNA extraction was performed using Trizol (Invitrogen). Poly(A) mRNA isolation from total RNA and fragmentation were performed using the Illumina Truseq RNA Sample Prep Kit with poly-T oligo-attached magnetic beads, according to the manufacturer's instructions. Reverse transcription of RNA fragments was performed using Superscript II reverse transcriptase (Life Technologies). The adaptor-ligated library was size-selected by band excision after agarose gel electrophoresis and purified using the QIAquick gel extraction kit (Qiagen). The prepared mRNA-sequencing libraries were pair-end sequenced on an Illumina Hi-seq 2500. The accession number for the mRNA-sequencing data in this paper is GSE83338.
Analysis of mRNA-sequencing data. After removing adapter sequences (TrueSeq universal and index adapters), we used cutadapter software 66 to trim the reads that PHRED scores lower than 20. Remaining reads were aligned to the mouse reference genome (GRCm38) using TopHat aligner 67 . After the alignment, we quantified the expression of genes as Fragments Per Kilobase of transcript per Million mapped reads (FPKM) for each gene using Cufflinks 68 . To identify the DEGs, we first selected the 'expressed' genes as the ones with FPKM larger than 1 under at least one of the eight samples. For the expressed genes, log 2 (FPKM + 1) values were normalized across eight samples using the quantile normalization method. To identify the DEGs, for each gene, we calculated a T-statistic and log 2 -fold-change in the comparisons of RORα LKO /RORα f/f HFD and RORα LKO / RORα f/f CD . We then estimated empirical distributions of T-statistics and log 2 -fold changes for the null hypothesis by random permutation of the eight samples (1000 permutations). On the basis of the distributions, for each gene, we computed adjusted P values for the observed T-statistic and log 2 -fold-change and the combined these P values with Stouffer's method 69 . Finally, we identified the DEGs as the ones that have the combined P-value ≤ 0.05 and absolute log 2 -fold-change ≥ 0.439, which is a cutoff value (the 95th percentile of the empirical distribution for log 2 -fold changes) for each comparison. We further identified RORα-dependent genes under HFD condition as the ones with significant differences between the log 2 -fold-change in the two comparisons above (RORα LKO /RORα f/f HFD and RORα LKO /RORα f/f CD ) larger than 0.439.
Functional enrichment analysis and TF enrichment analysis. For the genes in Groups 1-8, enrichment analysis of GOBPs and KEGG pathways were performed using a DAVID software 34 . We selected the GOBPs and KEGG pathways with P-value < 0.05 as the ones represented by the genes analyzed. For the genes in Group 1, TF enrichment analysis was performed using a ChEA2 software 33 . Among the TF-target gene data, only mouse TF-target gene data were used for the enrichment analysis. We selected the TFs with P-value < 0.01 as the ones significantly regulating the genes in Group 1.
Luciferase reporter assay. HEK293T cells (ATCC) and Hep3B cells (Korean Cell
Line Bank) were grown and transiently transfected by using polyethylenimine (PEI) and turbofect (Thermo Scientific, R0531). All cell lines used in the study were regularly tested for mycoplasma contamination. For luciferase reporter assays, 1 × 10 5 cells were seeded in DMEM supplemented with 10% FBS and 1% antibiotics. 
